U.S. Paper and Forestry Products Stock News

Northern Oil and Gas recently drew investor attention with commentary highlighting its roughly 8% dividend yield, expanding production from over 11,000 wells, and negative free cash flow driven by rapid growth amid weaker energy prices. This combination of high income, a diversified non-operating asset base, and questions over dividend sustainability has sharpened the focus on how resilient the company’s cash generation really is. We’ll now examine how concerns about negative free cash flow...

Event overview and why it matters for Marcus & Millichap (MMI) IPA Capital Markets, a division of Marcus & Millichap (MMI), arranged US$93.5 million in construction financing for the office to residential conversion of 830 Third Avenue in Manhattan. The deal spotlights the firm’s role in large urban redevelopment projects. See our latest analysis for Marcus & Millichap. Against this backdrop, Marcus & Millichap’s recent office to residential financing news comes after a mixed share price...

CAVA Group (CAVA) is back in focus after a cluster of upbeat analyst opinions, fresh institutional buying, a new Chief Operations Officer, and the company’s largest menu launch yet all converged to reset expectations. See our latest analysis for CAVA Group. The latest menu launch, leadership change and fresh analyst coverage have arrived alongside a 30 day share price return of 26.7% and a year to date share price return of 19.1%. This comes even as the 1 year total shareholder return sits at...

Earlier this month, ZIM Integrated Shipping Services approved the election of Ron Hadassi and Ran Gritzerstein to its Board of Directors at the January 2, 2026 AGM, while investors were informed that the company is in advanced stages of a strategic review assessing multiple acquisition proposals. These board changes, combined with an ongoing review of potential buyers, highlight how ZIM’s governance and ownership structure could materially influence its future direction and capital...

If you are wondering whether Medline is offering fair value at its current price, this article walks you through what the numbers are saying and what that could mean for you. Medline shares recently closed at US$44.12, with returns of 8.9% over the last 7 days, 5.9% over the last 30 days, and 8.6% year to date, which has put the stock on more investors' radar. Recent company updates and sector commentary around medical suppliers have given investors more information to work with, which can...

Ambarella (AMBA) has drawn fresh attention after CES, where it introduced the CV7 edge AI vision chip and the Ambarella Developer Zone, moves aimed at supporting faster rollouts of edge AI applications. See our latest analysis for Ambarella. Those CES launches come after a choppy stretch for the stock, with a 1 day share price return of 6.39% contrasting with a 30 day return of 5.23% and a 1 year total shareholder return of 14.93%. This suggests that long term momentum has been weak even as...

Compañía de Minas BuenaventuraA (BVN) has drawn fresh attention after a strong past 3 months, with the share price showing a 35.20% total return and a 22.33% move over the past month. See our latest analysis for Compañía de Minas BuenaventuraA. That recent momentum sits on top of a much longer run, with a 1 year total shareholder return of 175.85% and a 3 year total shareholder return above 3x, while the current share price is US$34.68 after a small 1 day pullback. If this kind of move has...

Viridian Therapeutics recently announced that the FDA has accepted its Biologics License Application for thyroid eye disease drug veligrotug, granting Priority Review with a target decision date of June 30, 2026, while the company also progresses a European filing and pivotal phase 3 trials for elegrobart (VRDN-003). This cluster of regulatory milestones meaningfully advances Viridian’s thyroid eye disease franchise, concentrating attention on how its pipeline could reshape treatment options...

Disc Medicine (IRON) is back in focus after the FDA extended its review of the company’s experimental therapy bitopertin, citing questions around trial data integrity and potential abuse risk. See our latest analysis for Disc Medicine. Those FDA questions and the recent executive hire have played out against a softer tape, with the 7 day share price return of 9.23% and 90 day share price return of 18.63% contrasting with a 1 year total shareholder return of 21.78% and a very large 3 year...

Why Benchmark Electronics is in Focus After a CTO Change Benchmark Electronics (BHE) is back on investor radars after appointing Josh Hollin as Senior Vice President and Chief Technology Officer, following the planned retirement of long serving engineering leader Jan Janick. See our latest analysis for Benchmark Electronics. The CTO transition comes after a stretch of firm price momentum, with a 7 day share price return of 9.86% and a 90 day share price return of 15.71%. The 5 year total...

Shift4 Payments, Inc. recently declared a US$1.50 per-share cash dividend on its 6% Series A Mandatory Convertible Preferred Stock, and refinanced about US$997,500,000.00 of term loans at lower interest margins under an amended first-lien credit agreement. At the same time, analysts have turned more cautious on Shift4’s organic growth prospects amid softer same-store sales in core hospitality and restaurant customers, even as new verticals and geographies contribute more. With Deutsche...

In recent days, United Therapeutics has faced a mix of developments, including insider share sales by senior executives, a completed Phase 3 Ralinepag trial in pulmonary arterial hypertension, and continued analyst coverage ahead of its January 12, 2026 presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Amid these events, analysts have highlighted Ralinepag’s trial completion and the Tyvaso franchise as key drivers for United Therapeutics’ long-term pulmonary...

Pomerantz LLP’s investigation into Cogent Communications Holdings (CCOI), following a near 6% year over year service revenue decline, a 98% dividend cut, and a sharp share price drop, has pushed the stock back into focus for investors. See our latest analysis for Cogent Communications Holdings. While the latest investigation and dividend cut hit sentiment hard, with a 90 day share price return decline of 46.22% and a 1 year total shareholder return decline of 64.93%, the recent 30 day share...

Illinois Tool Works announced that it will release its fourth-quarter and full-year 2025 results on February 3, 2026, followed by an earnings webcast and publication of presentation materials on its investor relations website. Analysts have recently highlighted Illinois Tool Works’ accelerating revenue growth and strong margin expansion, underpinned by customer-focused innovation, operating leverage, and cost simplification efforts that enhance its financial profile. Next, we examine how...

Recent attention on Danaos (DAC) centers on its shift to a net cash position, reduced liabilities, and robust balance sheet, which together help explain the stock’s performance over the past year. See our latest analysis for Danaos. At a share price of $99.36, Danaos has seen a 15.32% 90 day share price return, while its 1 year total shareholder return of 33.31% points to momentum that has built steadily rather than in a single spike, as investors have responded to its stronger balance sheet...

Why Electronic Arts Is Back On Investors’ Radar Electronic Arts (EA) has been drawing attention after its shares recently closed at US$204.25, prompting investors to reassess how the current price lines up with its business performance and prior returns. See our latest analysis for Electronic Arts. Recent moves in EA’s share price have been mild, but the 44.5% one year total shareholder return and 64.8% three year total shareholder return suggest longer term momentum has been stronger than...

If you are wondering whether Phillips 66 is still reasonably priced at around US$138.28, you are not alone. Many investors are asking whether the current market price lines up with the underlying value. The stock has had a mixed run recently, with a 2.7% decline over the last week, a 7.3% gain over the past month, a 5.9% return year to date, 19.0% over 1 year, 44.1% over 3 years, and 131.7% over 5 years. This naturally raises questions about what is already priced in. Recent coverage around...

Progress Software (PRGS) has been drawing attention after recent share price weakness. The stock has shown negative returns over the past month and over the past 3 months, prompting some investors to reassess its current valuation. See our latest analysis for Progress Software. Looking beyond the recent pullback, Progress Software’s share price return is soft over both the past quarter and year. The 1 year total shareholder return of a 36.3% decline and the broadly flat 5 year outcome suggest...

In recent days, several analysts reaffirmed positive views on Shoals Technologies Group, highlighting strengthening Battery Energy Storage System bookings and a growing order backlog following the appointment of David Van Bibber as Chief Accounting Officer. This combination of expanding BESS demand and leadership changes points to evolving business priorities that investors may see as important for Shoals’ long-term positioning. Now we'll explore how stronger BESS bookings and a record...

In recent days, analysts at Mizuho and Wells Fargo reiterated positive views on Mondelez International while flagging tougher competition and economic uncertainty, and investors have increased short interest in the stock to 40.16 million shares, or 3.49% of the float, below the sector average. At the same time, Mondelez has drawn interest from long-term investors such as Oakmark Global Fund, which views the company as a global snacking leader with strong pricing power and potential margin...

Westlake Royal Building Products, part of Westlake, recently showcased roofing brands and installation clinics at the 2026 International Roofing Expo, while Westlake completed its purchase of ACI/Perplastic Group’s global compounding solutions businesses across Portugal, Romania and Tunisia. This acquisition broadens Westlake’s Housing & Infrastructure Products reach in Europe and North Africa, potentially reshaping how investors view the balance between its building-products and...

Northern Trust recently confirmed that it has retained and expanded its more than 20-year mandate with Sweden’s AMF Tjanstepension AB, remaining custodian for AMF’s global pension assets while adding investment operations and trade services across the pension and fund company portfolios. This deepened relationship with a large pension client, alongside Northern Trust Asset Management’s new long-term Capital Market Assumptions, highlights how the group is aligning its asset servicing and...

If you are wondering whether Champion Homes at around US$96 per share is still reasonably priced or looking stretched, this article walks through what the numbers say about its current value. The stock has recently posted a 1.0% return over the last 7 days, 10.7% over the last 30 days, 13.4% year to date, 6.3% over 1 year, 68.7% over 3 years and 174.7% over 5 years. This naturally raises questions about how much of this performance is already reflected in the price. Recent news coverage has...

Market reaction to price drop and insider activity Dave (DAVE) is drawing attention today after a 12% share price drop on heavy trading volume, as investors weigh extensive insider share sales over the past six months and shifting institutional positions. See our latest analysis for Dave. The sharp 7 day share price return of negative 18.9% and wider year to date share price return of negative 11.6% contrast with a very large 3 year total shareholder return. This suggests strong long term...